General Information of Drug (ID: DM92E0W)

Drug Name
SCH-211803 Drug Info
Synonyms
SCH-211803; UNII-61GSP3D46U; CHEMBL12098; 61GSP3D46U; Sch211803; SCHEMBL12124213; ZINC3994912; BDBM50111346; L001654; (2-Amino-3-methylphenyl)(4-((4-((3-chlorophenyl)sulfonyl)phenyl)methyl)(1,4'-bipiperidin)-1'-yl)methanone; Piperidine, 1-(1-(3-methyl-2-aminophenyl)carbonylpiperidin-4-yl)-4-((3-chlorophenypsulphonylphenyl-4)methyl-); (2-Amino-3-methyl-phenyl)-{4-[4-(3-chloro-benzenesulfonyl)-benzyl]-[1,4'']bipiperidinyl-1''-yl}-methanone; Methanone, (2-amino-3-methylphenyl)(4-((4-((3-chlorophenyl)sulfonyl)phenyl)methyl
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9894173
CAS Number
CAS 331765-50-5
TTD Drug ID
DM92E0W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [3]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [4]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [5]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [6]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [7]
FP-1097 DMC1F2T Urinary incontinence MF50.2 Phase 2 [8]
PSD-506 DMT0KB1 Overactive bladder GC50.0 Discontinued in Phase 2 [9]
Otenzepad DMRXHAC Heart failure BD10-BD13 Discontinued in Phase 2 [10]
Alvameline DMLN0Y5 Alzheimer disease 8A20 Terminated [11]
HIMBACINE DMGAKD8 N. A. N. A. Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M2 (CHRM2) TTYEG6Q ACM2_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015639)
2 Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8.
3 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
4 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55.
5 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
6 Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7.
7 Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24.
8 Clinical pipeline report, company report or official report of FemmePharma.
9 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10 Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9.
11 In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40.
12 Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70.